A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.

被引：0
|
作者：
Eng, Cathy
Hart, Lowell L.
Severtsev, Aleksey
Gladkov, Oleg
Mueller, Lothar
Kopp, Mikhail V.
Vladimirov, Vladimir Ivanovich
Langdon, Robert M.
Kotiv, Bogdan
Barni, Sandro
Hsu, Ching
Bolotin, Ellen
Von Roemeling, Reinhard
Schwartz, Brian E.
Bendell, Johanna C.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Florida Canc Specialists SCRI, Ft Myers, FL USA
[3] Cent Clin Hosp 1 OAO, Moscow, Russia
[4] Chelyabinsk Reg Clin Oncol Ctr, Chelyabinsk, Russia
[5] Samara Reg Clin Oncol Dispensary, Samara, Russia
[6] State Med Inst Pyatigorsk, Pyatigorsk, Russia
[7] Nebraska Methodist Hosp, Omaha, NE USA
[8] State Educ Inst, High Profess Educ Mil Med Acad Named SM Kirov, St Petersburg, Russia
[9] Div Oncol, Treviglio, Italy
[10] Daiichi Sankyo Co Ltd, Edison, NJ USA
[11] ArQule Inc, Woburn, MA USA
[12] Sarah Cannon Res Inst, Nashville, TN USA
[13] Tennessee Oncol, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3508
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Predictive value of primary tumor location: Results from randomized phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)
    Tamura, T.
    Sakai, D.
    Sugimoto, N.
    Tokunaga, S.
    Tsuji, A.
    Ishida, H.
    Otsu, S.
    Moriwaki, T.
    Satake, H.
    Uchino, K.
    Matsumoto, S.
    Baba, E.
    Sato, M.
    Taniguchi, H.
    Kishimoto, J.
    Boku, N.
    Hyodo, I.
    Muro, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC)
    Watkins, David J.
    Ayers, Mark
    Cunningham, David
    Tabernero, Josep
    Tejpar, Sabine
    Kim, Tae-You
    Kim, Tae Won
    Kim, Sun Young
    Roh, Jae Kyung
    Beale, Philip James
    Park, Young Suk
    Guren, Tormod Kyrre
    Loboda, Andrey
    Nebozhyn, Michael
    Mogg, Robin
    Lunceford, Jared
    Schmidt, Emmett V.
    Brown, Holly M.
    Sathyanarayanan, Sriram
    Mauro, David J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)
    Bennouna, J.
    Hiret, S.
    Borg, C.
    Bertaut, A.
    Bouche, O.
    Deplanque, G.
    Francois, E.
    Conroy, T.
    Ghiringhelli, F.
    des Guetz, G.
    Seitz, J-F.
    Artru, P.
    Stanbury, T.
    Charpentier, S.
    Denis, M.
    Adenis, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] Phase I study of EMD 525797 (DI17E6), an antibody targeting αυβ integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-ras wild-type metastatic colorectal cancer.
    Elez, Elena
    Kocakova, Ilona
    Hoehler, Thomas
    Martens, Uwe Marc
    Bokemeyer, Carsten
    Van Cutsem, Eric
    Fram, Robert J.
    Bernard, Laurence
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G
    Sugimoto, Naotoshi
    Sakai, Daisuke
    Tamura, Takao
    Hara, Hiroki
    Nishina, Tomohiro
    Esaki, Taito
    Okuda, Hiroyuki
    Denda, Tadamichi
    Tsuda, Masahiro
    Satoh, Taroh
    Makiyama, Akitaka
    Yamazaki, Kentaro
    Kuramochi, Hidekazu
    Hosokawa, Ayumu
    Tsuda, Takashi
    Taniguchi, Hiroya
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [46] A BLINDED PLACEBO (P) CONTROLLED PHASE 1/2 DOSE ESCALATION STUDY (DES) OF BRIVANIB (B), AN ORAL SELECTIVE DUAL INHIBITOR OF FGF AND VEGF SIGNALING, IN COMBINATION WITH CETUXIMAB (C) AND IRINOTECAN (I) IN PATIENTS (PTS) WITH KRAS WILD TYPE (KWT) ADVANCED OR METASTATIC COLORECTAL CANCER (AMCRC): SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) FINDINGS
    Park, Y. S.
    El-Khoueiry, A.
    Cubillo, A.
    Pfeifer, P.
    Chacon, M.
    Amadori, D.
    Fokstuen, T.
    Chemidlin, J. M.
    Kollia, G.
    Nuyten, D. S. A.
    ANNALS OF ONCOLOGY, 2010, 21 : 199 - 199
  • [47] Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study
    Moretto, Roberto
    Battaglin, Francesca
    Antoniotti, Carlotta
    Buggin, Federica
    Delliponti, Laura
    Bergamo, Francesca
    Cremolini, Chiara
    Brunello, Antonella
    Schirripa, Marta
    Menichetti, Alice
    Salvatore, Lisa
    Marsico, Valentina Angela
    Rossini, Daniele
    Rumano', Laura
    Marmorino, Federica
    Falcone, Alfredo
    Zagonel, Vittorina
    Loupakis, Fotios
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).
    Cheng, Ann-Lii
    Cornelio, Gerardo H.
    Shen, Lin
    Price, Timothy Jay
    Yang, Tsai-Shen
    Chung, Ik-Joo
    Dai, Guanghai
    Lin, Jen-Kou
    Sharma, Atul
    Yeh, Kun-Huei
    Ma, Brigette
    Zaatar, Adel
    Guan, Zhongzhen
    Masood, Nehal
    Srimuninnimit, Vichien
    Yau, Thomas Cheung
    Sarholz, Barbara
    Lim, Robert S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
    Stintzing, Sebastian
    Jung, Andreas
    Rossius, Lisa
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Al-Batran, Salah-Eddin
    Vehling-Kaiser, Ursula
    Heintges, Tobias
    Moehler, Markus
    Scheithauer, Werner
    Kirchner, Thomas
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [50] Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
    Stintzing, Sebastian
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmuller, Christian A.
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Held, Swantje
    Giessen, Clemens Albrecht
    Moehler, Markus Hermann
    Jung, Andreas
    Kirchner, Thomas
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345